CAS 807640-87-5

JNJ-26483327

Description:

JNJ-26483327, with the CAS number 807640-87-5, is a chemical compound that belongs to the class of small molecules developed for therapeutic applications, particularly in the field of oncology. It is characterized by its specific molecular structure, which includes various functional groups that contribute to its biological activity. This compound acts as a selective inhibitor of certain kinases, which are enzymes that play a crucial role in cell signaling pathways related to cancer cell proliferation and survival. The inhibition of these kinases can lead to the suppression of tumor growth and may enhance the effectiveness of other cancer treatments. JNJ-26483327 has undergone various stages of preclinical and clinical testing to evaluate its efficacy and safety profile. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are also critical for determining its potential as a therapeutic agent. Overall, JNJ-26483327 represents a promising candidate in the ongoing search for effective cancer therapies.

BGB-102

CAS: 807640-87-5

BGB-102

Purity: ≥98%

Molecular weight: 457.36g/mol

Ref: 54-BUP00444

BGB-102

CAS: 807640-87-5

BGB-102 is a monoclonal antibody that specifically binds to the amyloid beta peptide (Aβ) in Alzheimer's disease. It inhibits Aβ aggregation and promotes its clearance from the brain. BGB-102 has been shown to promote the degradation of Aβ in vitro and reduce amyloid plaques in animal models of Alzheimer's disease. The mechanism of action for BGB-102 remains unclear, but it may be due to its ability to bind to the receptor for advanced glycation end products (RAGE).

Formula: C₂₂H₂₅BrN₄O₂

Purity: Min. 95%

Molecular weight: 457.4 g/mol

Ref: 3D-HHB64087

BGB-102

CAS: 807640-87-5

BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.

Formula: C₂₂H₂₅BrN₄O₂

Purity: 99.02%

Color and Shape: Solid

Molecular weight: 457.36

Ref: TM-T10531